The pharmaceutical company’s robust performance in Q4 FY26 was driven by strong growth in its CDMO business, improved operational efficiency, and healthy demand across key markets.
Gland Pharma posted a 97% year-on-year jump in consolidated net profit to Rs 366.7 crore in Q4FY26, compared to Rs 186.5 crore in the corresponding quarter last year.
Revenue from operations increased 22% YoY to Rs 1,742.8 crore, against Rs 1,424.9 crore reported in Q4 FY25.
The company’s adjusted EBITDA for the quarter rose 51% year-on-year, while the adjusted EBITDA margin improved to 30%. For the full financial year FY26, adjusted EBITDA grew 33%, with margins standing at 26%.
The Contract Development and Manufacturing Organization (CDMO) business continued to be a major growth driver for the company. The segment contributed 46% of total revenues during Q4 FY26 and recorded a strong 36% YoY growth.
For the full FY26 period, CDMO revenues also contributed 46% of total sales and grew 28% year-on-year.Gland Pharma continued to strengthen its product pipeline through sustained research investments. Quarterly R&D spending stood at Rs 506 million, while full-year FY26 R&D investments reached Rs 2,230 million.
The Board of Directors recommended a final dividend of Rs 20 per equity share (2000%) on the face value of Rs 1 each for FY26. The dividend, subject to shareholder approval at the company’s 48th Annual General Meeting (AGM), is expected to be paid within 30 days from the date of approval.
Commenting on the results, Mr Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong FY26 performance, reflected in consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%, underscores the progress we are making across the businesses, including Cenexi. The 38% adjusted EBITDA margin of the base business has been supported by robust growth in the CDMO segment, alongside new product launches and improved profitability across our existing portfolio, driven by ongoing cost-efficiency initiatives. We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.”
Stock Performance and Technical Indicators
Over the last year, Gland Pharma shares have gained nearly 27%. The company currently commands a market capitalisation of about Rs 30,781 crore. Its 52-week high stands at Rs 2,131.
On the valuation front, the stock trades at a price-to-earnings (PE) ratio of 36.33 and a price-to-book (PB) ratio of 3.36.
Also read: Delhivery shares tumble 5% after Q4 results. Why Nuvama, Elara & other brokerages remain bullish
From a technical perspective, the stock’s 14-day Relative Strength Index (RSI) stands at 57.3, indicating neutral-to-positive momentum. An RSI below 30 is generally considered oversold, while an RSI above 70 is considered overbought. The stock is also trading above all 8 out of 8 key simple moving averages (SMAs), signaling continued bullish momentum.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
